41 related articles for article (PubMed ID: 38054270)
1. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
Zhu Y; Yang Q; Liu K; Cao H; Zhu H
J Gynecol Oncol; 2024 Jan; 35(1):e2. PubMed ID: 37477106
[TBL] [Abstract][Full Text] [Related]
2. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D; Mouret-Reynier MA; Harter P; Cropet C; Caballero C; Wolfrum-Ristau P; Satoh T; Vergote I; Parma G; Nøttrup TJ; Lebreton C; Fasching PA; Pisano C; Manso L; Bourgeois H; Runnebaum I; Zamagni C; Hardy-Bessard AC; Schnelzer A; Fabbro M; Schmalfeldt B; Berton D; Belau A; Lotz JP; Gropp-Meier M; Gladieff L; Lück HJ; Abadie-Lacourtoisie S; Pujade-Lauraine E; Ray-Coquard I
Int J Gynecol Cancer; 2024 Apr; 34(4):550-558. PubMed ID: 38129136
[TBL] [Abstract][Full Text] [Related]
3. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Hettle R; McCrea C; Lee CK; Davidson R
Ther Adv Med Oncol; 2021; 13():17588359211049639. PubMed ID: 34616492
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer.
Lai SP; Wang SY; Chan AL; Leung JH; Yip HT
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):541-549. PubMed ID: 38372034
[TBL] [Abstract][Full Text] [Related]
5. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
J Neurooncol; 2024 Apr; ():. PubMed ID: 38563851
[TBL] [Abstract][Full Text] [Related]
6. Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.
Zhu Y; Lin Y; Liu K; Zhu H
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38576343
[TBL] [Abstract][Full Text] [Related]
7. Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer at a single institution: A retrospective study.
Katsuda T; Nishio S; Tasaki S; Park J; Tasaki K; Tsuda N; Ushijima K
J Obstet Gynaecol Res; 2024 May; ():. PubMed ID: 38742699
[TBL] [Abstract][Full Text] [Related]
8. Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable?
Klag N; Walter AC; Sheely KM; Manahan KJ; Geisler JP
Clinicoecon Outcomes Res; 2016; 8():287-91. PubMed ID: 27382318
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain.
Crespo C; Moreno E; Sierra J; Serip S; Rubio M
Health Econ Rev; 2013 Dec; 3(1):28. PubMed ID: 24314138
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.
Gros B; Galán A; González-Parra E; Herrero JA; Echave M; Vegter S; Tolley K; Oyagüez I
Health Econ Rev; 2015 Dec; 5(1):49. PubMed ID: 26062537
[TBL] [Abstract][Full Text] [Related]
11. Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer.
Agnihotri N; Ambavane A; Fan L; Li W; Yoo H; Joo S; Muston D
Pancreatology; 2024 Mar; 24(2):271-278. PubMed ID: 38286712
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
Zhu Y; Liu K; Cao H; Zhu H
J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
[TBL] [Abstract][Full Text] [Related]
14. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.
Cedillo S; Garí C; Aceituno S; Manso L; Cercos Lleti AC; Ventayol Bosch P; Casado A; Perez Fidalgo A
Int J Gynecol Cancer; 2023 Dec; ():. PubMed ID: 38054270
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D; Fan L; Mihai A; Moustaid FE; Simmons D; Monberg M; Muston D
Pharmacoecon Open; 2022 Nov; 6(6):811-822. PubMed ID: 36036344
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
